An interventional study of Connected actimeter to measure physical activity in OSA patients and Connected BORA Band to measure physical activity in COPD patients only in Sleep Apnea, Obstructive and Chronic Obstructive Pulmonary Disease, sponsored by University Hospital, Grenoble. Recruiting at 2 sites in France. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-01-03.
Sponsored by University Hospital, Grenoble · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 48 studies in Sleep Apnea, Obstructive by University Hospital, Grenoble — 6 open to participants now, 6 under way, none of them phase 3. Sleep Apnea, Obstructive · University Hospital, Grenoble.
Among the 48 studies in Sleep Apnea, Obstructive by University Hospital, Grenoble, this one has the largest planned enrollment of the 32 interventional ones that give a count, is one of 3 that started in 2021, is one of 25 with no phase, and was the 42nd registered.
2,246 studies on the registry are indexed under Sleep Apnea, Obstructive; 476 are open to participants now.
Browse Sleep Apnea, Obstructive studies →6 of the 48 studies in Sleep Apnea, Obstructive by University Hospital, Grenoble are open now, in 1 country. Recruiting first, the newest first:
University Hospital, Grenoble · Sites in France
Ages 18–75
University Hospital, Grenoble · Sites in France
Ages 18–85
University Hospital, Grenoble · Sites in France
Ages 18+
University Hospital, Grenoble · Sites in France
Ages 18–80
University Hospital, Grenoble · Sites in France
Ages 18–85
By country, each count listing its studies:
Of the 317 Sleep Apnea, Obstructive studies recruiting now, 149 (47%) set no upper age limit and 124 (39%) stop at 75 or younger; 53 take children under 18; 66 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
48 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 3 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 400 is above the median of 52 across 1,476 interventional studies indexed under Sleep Apnea, Obstructive.
Median enrollment 54 across the 32 interventional studies, 158 across the 16 observational. Of the 29 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
University Hospital, Grenoble is the lead sponsor of 838 studies on the registry; 208 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 48 studies in Sleep Apnea, Obstructive by University Hospital, Grenoble, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Chronic respiratory diseases such as obstructive sleep apnea syndrome (OSA) and chronic obstructive pulmonary disease (COPD) constitute a major public health problem, due to their high prevalence, but especially because of their cardiovascular and metabolic morbidity and mortality and the associated costs for the health system. The organization of long-term management of these diseases is now part of the e-health process, digital health with the use of massive "big data" generated by care and follow-up. Therapeutic patient education and the integration of connected objects will allow personalized therapeutic education support with interventions by local medical staff adapted to the needs of the patients.
This will also allow to objectify the effect of treatments such as continuous positive airway pressure (CPAP) for OSA or non-invasive ventilation (NIV) and/or oxygen therapy for COPD, not only on the prevention of respiratory decompensation but also on cardiovascular and metabolic risk factors which are major elements of the prognosis. This project will therefore make it possible to demonstrate the feasibility and to deploy a multi-actor care pathway in the territory.
The investigators propose a prospective clinical study, conducted at the Verdun Hospital, with the main objective of studying the evolution of the quality of life of patients with a chronic respiratory pathology, during an integrated management at home for 6 months.
The secondary objectives:
To study the evolution of the following parameters, before treatment (at inclusion) and after 6 months of integrated management:
Chronic respiratory diseases such as obstructive sleep apnea syndrome (OSA) and chronic obstructive pulmonary disease (COPD) constitute a major public health problem, due to their high prevalence, but especially because of their cardiovascular and metabolic morbidity and mortality and the associated costs for the health system. There is also an inequality of access to referral care linked to demographics and territorial organization. We are currently at a turning point in the understanding of these pathologies and their coordinated management by combining therapeutic modalities. The organization of long-term management of these diseases is now part of the e-health process, digital health with the use of massive "big data" generated by care and follow-up. Therapeutic patient education and the integration of connected objects measuring weight, oxygen saturation rate, heart rate, respiratory rate, skin temperature blood pressure or physical activity will allow personalized therapeutic education support with interventions by local medical staff adapted to the needs of the patients.
This will also allow to objectify the effect of treatments such as continuous positive airway pressure (CPAP) for OSA or non-invasive ventilation (NIV) and/or oxygen therapy for COPD, not only on the prevention of respiratory decompensation but also on cardiovascular and metabolic risk factors which are major elements of the prognosis. This project will therefore make it possible to demonstrate the feasibility and to deploy a multi-actor care pathway in the territory.
The investigators propose a prospective clinical study, conducted at the Verdun Hospital, with the main objective of studying the evolution of the quality of life of patients with a chronic respiratory pathology, during an integrated management at home for 6 months.
The secondary objectives:
To study the evolution of the following parameters, before treatment (at inclusion) and after 6 months of integrated management:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
OSA or COPD patients having an integrated management at home using connected devices, during 6 months
Device: Connected actimeter to measure physical activity in OSA patients · Device: Connected BORA Band to measure physical activity in COPD patients only · Other: IPAQ to evaluated physical activity · Device: Connected scale to measure weight · Device: Connected tensiometer to measure arterial pressure · Device: Connected BORA Band to measure oxygen saturation in COPD patients only · Device: Connected BORA Band to measure heart rate in COPD patients only · Device: Connected BORA Band to measure respiratory rate in COPD patients only · Other: EXASCORE to evaluated COPD severity · Other: Epworth scale to evaluate sleepiness · Other: Pichot scale to evaluate fatigue · Other: Usability questionnaire · Other: SF36 questionnaire
Connected actimeter worn for one week before initiation of treatment, at M3 and at M6, to measure average daily steps for OSA patients
Connected BORA Band worn for one week before initiation of treatment, at M3 and at M6, to measure average daily steps for COPD patients only
Physical activity evaluated by IPAQ (International Physical Activity Questionnaire) at the inclusion, M3 and M6
Weight measured by a connected scale, before CPAP or NIV treatment, at M3 and M6
Arterial pressure measured by a connected tensiometer, before CPAP or NIV treatment, at M3 and M6
Daily oxygen saturation measured by the connected BORA Band for COPD patients only during 6 months
Daily heart rate measured by the connected BORA Band for COPD patients only during 6 months
Daily respiratory rate measured by the connected BORA Band for COPD patients only during 6 months
COPD severity evaluated by the EXASCORE questionnaire at inclusion, M3 and M6 for COPD patients only
Sleepiness evaluated by the Epworth scale at baseline, M3 and M6
Fatigue evaluated by the Pichot scale at inclusion, M3 and M6
Subjective assessment of each device by means of usability questionnaire at M6
Quality of life evaluated by the SF36 questionnaire at inclusion and M6
Change of Quality of life assessed by the SF36 questionnaire
Change of quality of life, assessed by the SF36 questionnaire, from Baseline (at inclusion) and after 6 months of an integrated management at home
Time frame: at inclusion and at 6 months
Change of Physical activity (average daily steps) for OSA patient only
Change of the physical activity using a connected actimeter for OSA patients only, from Baseline (one week before treatment) and after 3 and 6 months of an integrated management at home
Time frame: One week before initiation of CPAP treatment and at Month 3 and Month 6
Change of Physical activity (average daily steps) for COPD patient only
Change of the physical activity using the connected BORA Band for COPD patients only, from Baseline (one week before treatment) and after 3 and 6 months of an integrated management at home
Time frame: One week before initiation of NIV treatment and at Month 3 and Month 6
Change of Physical activity assessed by the IPAQ questionnaire
Change of Physical activity assessed by the IPAQ (International Physical Activity Questionnaire), from Baseline (at inclusion) and after 3 and 6 months of an integrated management at home
Time frame: At the inclusion, Month 3 and Month 6
Change of Weight measured by a connected scale
Change of Weight measured by a connected scale, from Baseline (before CPAP or NIV treatment), and after 3 and 6 months of an integrated management at home.
Time frame: Before CPAP or NIV treatment, at Month 3 and Month 6
Change of Arterial pressure measured by a connected tensiometer
Change of Arterial pressure measured by a connected tensiometer, from Baseline (before CPAP or NIV treatment), and after 3 and 6 months of an integrated management at home.
Time frame: Before CPAP or NIV treatment, at Month 3 and Month 6
Daily oxygen saturation measured by the connected BORA Band for COPD patients only
Daily oxygen saturation measured by the connected BORA Band for COPD patients only
Time frame: During 6 months
Daily heart rate measured by the connected BORA Band for COPD patients only
Daily heart rate measured by the connected BORA Band for COPD patients only
Time frame: During 6 months
Daily respiratory rate measured by the connected BORA Band for COPD patients only
Daily respiratory rate measured by the connected BORA Band for COPD patients only
Time frame: During 6 months
Change of COPD severity evaluated by the EXASCORE questionnaire for COPD patients only
Change of COPD severity evaluated by the EXASCORE questionnaire for COPD patients only, from Baseline (at inclusion), and after 3 and 6 months of an integrated management at home.
Time frame: At the inclusion, Month 3 and Month 6
Change of Sleepiness evaluated by the Epworth questionnaire
Change of Sleepiness evaluated by the Epworth questionnaire, from Baseline (at inclusion), and after 3 and 6 months of an integrated management at home.
Time frame: At baseline, Month 3 and Month 6
Change of Fatigue evaluated by the Pichot questionnaire
Change of Fatigue evaluated by the Pichot questionnaire, from Baseline (at inclusion), and after 3 and 6 months of an integrated management at home.
Time frame: At inclusion, Month 3 and Month 6
Satisfaction and usage of the connected scale assessed by a specific questionnaire
Satisfaction and usage of the connected scale assessed by a specific questionnaire, after 6 months of an integrated management at home
Time frame: At Month 6
Satisfaction and usage of the connected tensiometer assessed by a specific questionnaire
Satisfaction and usage of the connected tensiometer assessed by a specific questionnaire, after 6 months of an integrated management at home
Time frame: At Month 6
Satisfaction and usage of the connected actimeter assessed by a specific questionnaire, for OSA patients only
Satisfaction and usage of the connected actimeter assessed by a specific questionnaire, for OSA patients only, after 6 months of an integrated management at home
Time frame: At Month 6
Satisfaction and usage of the connected BORA Band assessed by a specific questionnaire, for COPD patients only
Satisfaction and usage of the connected BORA Band assessed by a specific questionnaire, for COPD patients only, after 6 months of an integrated management at home
Time frame: At Month 6
Plan to share: No
No publications or documents are linked to this record.
Started Sep 2021 (actual). Primary completion is estimated for Dec 2024, 39 months after the start.
Of 511 non-industry interventional studies with no phase under Sleep Apnea, Obstructive, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 53. This study's planned 39 months is above that.
Counting every sponsor, half of 629 studies reached it within 27 months; a quarter within 12 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Grenoble →